机构：[1]Department of Thoracic Surgery, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China[2]Department of Thoracic Surgery,Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China[3]Department of Thoracic Surgery, Shanghai General Hospital,Shanghai Jiao Tong University, Shanghai 200080, China[4]Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao266001, China[5]Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China[6]Department of Endocrinology,Tianjin Medical University General Hospital, Tianjin 300052, China[7]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu 610041,China外科中心胸外科中心四川省肿瘤医院胸外科[8]Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China[9]Department of Thoracic Surgery, FirstAffiliated Hospital of Anhui Medical University, Hefei 230022, China[10]Department of Thoracic Surgery, Affiliated Cancer Hospital of ZhengzhouUniversity, Zhengzhou 450008, China[11]Department of Thoracic Surgery, Beijing Cancer Hospital, Beijing 100142, China[12]Department ofCardiothoracic Surgery, Changhai Hospital, Shanghai 200433, China[13]Department of Thoracic Surgery, Liaoning Cancer Hospital, Shenyang110042, China[14]Department of Thoracic Surgery, First Affiliated Hospital of Jilin University, Changchun 130021, China[15]Department ofThoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[16]Department of Thoracic Surgery, Huashan Hospital,Fudan University, Shanghai 200032, China[17]Department of Esophageal Cancer, Tianjin Cancer Hospital, Tianjin 300060, China[18]Department ofThoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China浙江省肿瘤医院[19]Department of Thoracic Surgery, Jiangxi People’s Hospital, Nanchang330006, China[20]Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, CollaborativeInnovation Center of Cancer Medicine, Guangzhou 510060, China
Background: Postoperative radiotherapy (PORT) for thymic tumor is still controversial. The object of the study is to evaluate the role of PORT for stage I to III thymic tumors. Methods: The Chinese Alliance for Research in Thymomas (ChART) was searched for patients with stage I to III thymic tumors who underwent surgical resection without neoajuvant therapy between 1994 and 2012. Univariate and multivariate survival analyses were performed. Cox proportional hazard model was used to determine the hazard ratio for death. Result: From the ChART database, 1,546 stage I to III patients were identified. Among these patients, 649 (41.98%) received PORT. PORT was associated with gender, histological type (World Health Organization, WHO), thymectomy extent, resection status, Masaoka-Koga stage and adjuvant chemotherapy. The 5-year and 10-year overall survival (OS) rates and disease-free survival (DFS) rates for patients underwent surgery followed by PORT were 90% and 80%, 81% and 63%, comparing with 96% and 95%, 92% and 90% for patients underwent surgery alone (P=0.001, P<0.001) respectively. In univariate analysis, age, histological type (WHO), Masaoka-Koga stage, completeness of resection, and PORT were associated with OS. Multivariable analysis showed that histological type (WHO) (P=0.001), Masaoka-Koga stage (P=0.029) and completeness of resection (P=0.003) were independently prognostic factors of OS. In univariate analysis, gender, myasthenia gravis, histological subtype, Masaoka-Koga stage, surgical approach, PORT and completeness of resection were associated with DFS. Multivariate analysis showed that histological subtype (P<0.001), Masaoka- Koga stage (P=0.005) and completeness of resection (P=0.006) were independent prognostic factors for DFS. Subgroup analysis showed that patients with incomplete resection underwent PORT achieved better OS and DFS (P=0.010, 0.017, respectively). However, patients with complete resection underwent PORT had the worse OS and DFS (P<0.001, P<0.001, respectively). Conclusions: The current retrospective study indicates that PORT after incomplete resection could improve OS and DFS for patients with stage I to III thymic tumors. However for those after complete resection, PORT does not seem to have any survival benefit on the whole.
第一作者机构：[1]Department of Thoracic Surgery, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China[2]Department of Thoracic Surgery,Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China[*1]Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, 561 Dongfeng Road East, Guangzhou, Guangdong 510060, China.[*2]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai Road West, Shanghai 200030, China.
推荐引用方式(GB/T 7714)：
Qianwen Liu,Zhitao Gu,Fu Yang,et al.The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database[J].JOURNAL OF THORACIC DISEASE.2016,8(4):687-695.doi:10.21037/jtd.2016.03.28.
APA：
Qianwen Liu,Zhitao Gu,Fu Yang,Jianhua Fu,Yi Shen...&Members of the Chinese Alliance for Research in Thymomasa.(2016).The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database.JOURNAL OF THORACIC DISEASE,8,(4)
MLA：
Qianwen Liu,et al."The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database".JOURNAL OF THORACIC DISEASE 8..4(2016):687-695
